Activating KRAS mutations in CRC tumor samples are an early event in the progression of colon carcinoma and the only predictive molecular marker useful for treatment decision as EGFR directed therapy is ineffective in the context of concomitant KRAS mutation [26]. The gene discussed is KRAS; the disease is colon carcinoma.